4344-73-4

Usage

Uses

Used in Pharmaceutical and Medicinal Applications:
1,2,4,5,6,7-Hexahydro-indazol-3-one is used as a building block for the synthesis of biologically active molecules, contributing to the development of new pharmaceutical agents.
Used in Organic Synthesis:
1,2,4,5,6,7-Hexahydro-indazol-3-one is used as a building block for the construction of diverse chemical structures, facilitating the creation of novel compounds with potential applications in various fields.
Used in Antimicrobial Applications:
1,2,4,5,6,7-Hexahydro-indazol-3-one is used as an antimicrobial agent, exhibiting potential activity against various microorganisms, which could be beneficial in the development of new antimicrobial drugs.
Used in Anticonvulsant Applications:
1,2,4,5,6,7-Hexahydro-indazol-3-one is used as an anticonvulsant agent, showing potential in the management of seizure disorders, warranting further research for its therapeutic potential in neurological conditions.

Upstream product

• 13054-47-2 4,5,6,7-tetrahydro-benzo[c]isoxazol-3-ylamine 
• 16064-21-4 2-sulfanylidene-1,2,3,4,5, 6,7,8-octahydroquinazolin-4-one 
• 34170-21-3 2-methylsulfanyl-5.6.7.8-tetrahydro-3H-quinazolin-4-one 
• 41302-34-5 2-(methoxycarbonyl)cyclohexanone 
• 1655-07-8 ethyl 2-oxocyclohexane carboxylate 
• 107154-16-5 2-methylsulfanyl-3-phenyl-5,6,7,8-tetrahydro-3H-quinazolin-4-one 
• 7803-57-8 hydrazine hydrate 
• 7364-25-2 1H-indazol-3-ol 

Downstream Products

• 52046-92-1 1-benzyl-3-<3-(dimethylamino)propoxy>-4,5,6,7-tetrahydro-1H-indazole 
• 1022144-67-7 C₂₅H₂₅N₅O₅ 
• 7364-25-2 3-indazolinone 
• 19462-59-0 3,4-tetramethylene-4-chloro-2-pyrazolin-5-one 

Relevant academic research and scientific papers

COMPOUNDS AS GLP-1R AGONISTS

The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing. Also provided are pharmaceutical compositions containing such compounds, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing. Methods of prepare these compounds and compositions and method of using them to treat or present a disease or a condition mediated by GLP-1R.

COMPOUNDS FOR THE TREATMENT OF HIV

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

The present invention encompasses compounds of Formula (I) as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also

Indazole compounds, and their production and use

A compound of the formula: STR1 wherein R is a C1 -C5 alkyl group, a C3 -C4 alkenyl group, a C3 -C4 alkynyl group or a C1 -C3 alkoxy(C1 -C2)alkyl

Synthesis of 1-Substituted 3-(Dialkylaminoalkoxy)-4,5,6,7-tetrahydro-1H-indazoles

4,5,6,7-Tetrahydro-3-indazolone was prepared by catalytic hydrogenation of 3-indazolone, and its reaction with dialkylaminoalkyl chloride was studied.In addition, a number of 1-substituted 3-(dialkylaminoalkoxy)-4,5,6,7-tetrahydro-1H-indazoles were prepar